| Symbol | ADPT |
|---|---|
| Name | ADAPTIVE BIOTECHNOLOGIES CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 1165 EASTLAKE AVE E, SEATTLE, WA 98109 |
| Telephone | 206-659-0067 |
| Fax | — |
| — | |
| Website | https://www.adaptivebiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001478320 |
| Description | Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Additional info from NASDAQ: |
📋 Harlan Robins (Officer) plans to sell 492K shares of Adaptive Biotechnologies Corporation (at $22.58 each, total $11.1M) Filed: Jul 21, 2026 | ID: 000463
Read moreBOBULSKY SUSAN 🔴 sold 5.0K shares of Adaptive Biotechnologies Corp (ADPT) at $23.00 Transaction Date: Jul 16, 2026 | Filing ID: 000016
Read moreLO FRANCIS 🟡 adjusted position in 105.8K shares (3 derivative) of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($4.3M) Transaction Date: Jul 15, 2026 | Filing ID: 000019
Read more📋 SUSAN BOBULSKY (Officer) plans to sell 5K shares of ADAPTIVE BIOTECHNOLOGIES CORPORATION (at $22.90 each, total $114K) Filed: Jul 16, 2026 | ID: 007171
Read moreROBINS HARLAN S 🔴 sold 386.2K shares of Adaptive Biotechnologies Corp (ADPT) at $22.45 ($8.5M) Transaction Date: Jul 02, 2026 | Filing ID: 000015
Read moreLO FRANCIS 🟡 adjusted position in 95.8K shares (8 derivative) of Adaptive Biotechnologies Corp (ADPT) at $22.59 ($3.5M) Transaction Date: Jul 01, 2026 | Filing ID: 000017
Read moreBOBULSKY SUSAN 🔴 sold 487 shares of Adaptive Biotechnologies Corp (ADPT) at $22.00 Transaction Date: Jul 01, 2026 | Filing ID: 000014
Read more📋 Harlan Robins (Officer) plans to sell 386K shares of Adaptive Biotechnologies Corporation (at $21.19 each, total $8.2M) Filed: Jul 02, 2026 | ID: 000428
Read moreBENZENO SHARON 🟡 adjusted position in 165.8K shares (5 derivative) of Adaptive Biotechnologies Corp (ADPT) at $21.14 ($5.3M) Transaction Date: Jun 26, 2026 | Filing ID: 000008
Read moreBOBULSKY SUSAN 🔴 sold 5.0K shares of Adaptive Biotechnologies Corp (ADPT) at $20.50 Transaction Date: Jun 25, 2026 | Filing ID: 000012
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06828991 | A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patient… | Phase2 | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting | 2025-09-04 | 2030-04-01 | ClinicalTrials.gov |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgki… | Phase2 | Lymphoma | Not_Yet_Recruiting | 2025-06-01 | 2028-03-30 | ClinicalTrials.gov |
| NCT05769829 | ImmuneSense™ IBD Study | — | Inflammatory Bowel Diseases | Terminated | 2022-10-31 | 2023-08-14 | ClinicalTrials.gov |
| NCT05255354 | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing… | — | Follicular Lymphoma | Recruiting | 2022-06-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05271630 | Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cel… | — | Multiple Myeloma | Active_Not_Recruiting | 2022-04-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT05112874 | ImmuneSense™ COVID-19 Cross-Reactivity Study | — | Coronavirus Disease | Withdrawn | 2021-12-15 | 2023-05-17 | ClinicalTrials.gov |
| NCT05054088 | ImmuneSense COVID-19 Variant Study | — | Covid19 | Completed | 2021-10-12 | 2022-07-28 | ClinicalTrials.gov |
| NCT04545333 | The clonoSEQ® Watch Registry | — | Acute Lymphoblastic Leukemia, Adult B-Cell | Terminated | 2020-10-13 | 2023-10-01 | ClinicalTrials.gov |
| NCT04583982 | ImmuneSense™ COVID-19 Study | — | Coronavirus Disease (COVID-19) | Completed | 2020-10-09 | 2020-12-04 | ClinicalTrials.gov |
| NCT04422314 | ImmuneSense Lyme Study | — | Lyme Disease | Completed | 2020-07-09 | 2021-10-30 | ClinicalTrials.gov |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize E… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Active_Not_Recruiting | 2020-05-13 | 2027-05-01 | ClinicalTrials.gov |
| NCT04494893 | ImmuneRACE - Immune Response Action to COVID-19 Events | — | Covid19 | Completed | 2020-04-24 | 2021-04-23 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Venetoclax with anti CD20 monoclonal antibody | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | Drug | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| clonoSEQ Assay | Other | Preclinical | Acute Lymphoblastic Leukemia, Adult B-Cell | TERMINATED | NCT04545333 |
| T-Detect™ SARS-CoV-2 Assay | Other | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04583982 |
| T-Detect Lyme | Other | Preclinical | Lyme Disease | COMPLETED | NCT04422314 |
| T-Detect COVID test | Other | Preclinical | Covid19 | COMPLETED | NCT05054088 |
| ClonoSEQ | Other | Preclinical | Follicular Lymphoma | RECRUITING | NCT05255354 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| Bendamustine | Other | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| ClonoSEQ | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Mosunetuzumab | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Venetoclax with anti CD20 monoclonal antibody | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | Drug | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Proteasome Inhibitor | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Immunomodulatory Agent | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Autologous Stem Cell Transplant | Other | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| T-Detect™ SARS-CoV-2 Assay | OTHER | Preclinical | Coronavirus Disease (COVID-19) | COMPLETED | NCT04583982 |
| T-Detect COVID test | DEVICE | Preclinical | Covid19 | COMPLETED | NCT05054088 |
| Rituximab | DRUG | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| Bendamustine | DRUG | Phase PHASE2 | Lymphoma | NOT_YET_RECRUITING | NCT06557330 |
| ClonoSEQ | DEVICE | Preclinical | Follicular Lymphoma | RECRUITING | NCT05255354 |
| Mosunetuzumab | DRUG | Phase PHASE2 | Diffuse Large B-Cell Lymphoma (DLBCL) | RECRUITING | NCT06828991 |
| Venetoclax with anti CD20 monoclonal antibody | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Venetoclax monotherapy | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | ACTIVE_NOT_RECRUITING | NCT04419519 |
| Proteasome Inhibitor | DRUG | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Immunomodulatory Agent | DRUG | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |
| Autologous Stem Cell Transplant | OTHER | Preclinical | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05271630 |